Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Medarex To Receive Amgen Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Medarex To Receive Amgen Milestone

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Medarex, Inc. expects to receive an undisclosed milestone payment from its licensing partner, Amgen Inc., for the advancement of an antibody into clinical trials. The antibody was developed using Medarex’s UltiMAb technology and is the fourth UltiMAb-derived antibody in clinical development by Amgen. Medarex may receive future milestone payments and royalties should this product candidate progress through clinical development and to the market.

“We are pleased with the development progress that Amgen continues to make with our fully human antibody technology,” said Irwin Lerner, chairman of the board of directors and interim president and chief executive officer of Medarex. “We believe that Amgen’s proven product development experience has been key to their advancing the four UltiMAb antibodies into clinical trials.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics